从1967年到2023年,关于因失眠药物而发作的不良事件报告
Tae Hyeon Kim1,2, Kyeongmin Lee2,3, Jiyoung Hwang2
1Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
Scientific reports
|July 27, 2025
概括
失眠药物可以增加发作风险,其中二类药物和抗抑郁药具有最高风险. 素受体对抗剂和黑激素受体激动剂在患有的患者中似乎更安全.
科学领域:
- 药物监督 药物监督 药物监督
- 神经学 神经学
- 睡眠医学 睡眠医学
背景情况:
- 失眠会对控制产生负面影响,但证据有限.
- 确定易发作患者的安全失眠治疗方法至关重要.
研究的目的:
- 分析与各种失眠药物相关的发作风险.
- 为高风险患者确定更安全的失眠药物选择.
主要方法:
- 使用VigiBase,这是一个全球药监数据库 (1967-2023年).
- 分析了对失眠药物和发作风险的不良药物反应报告.
- 使用报告的赔率比率 (ROR) 和信息组件 (IC) 评估的关联.
主要成果:
- 在失眠药物和发作之间发现了显著的整体关联 (ROR 2.12).
- 型抗抑郁药 (ROR 2.56) 和抗抑郁药 (ROR 2.52) 的发作风险最高.
- 素受体对抗剂 (ROR 0.81) 和黑激素受体对抗剂 (ROR 1.20) 与发作没有显著的关联.
结论:
- 在不同类型的失眠药物中,发作风险存在显著差异.
- 素受体对抗剂和黑激素受体激动剂可能是患有的患者更安全的替代品.
相关概念视频
Sedatives and Hypnotics Drugs: Miscellaneous Agents
243
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
243
Antiepileptic Drugs: Potassium Channel Activators
278
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
278
Epilepsy and Seizures: Overview
281
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
281
CNS Depressants: Barbiturates and Benzodiazepines
472
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
472
Management of Insomnia
323
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
323
Insomnia
127
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
127


